0
0
The U.S. Food and Drug Administration (FDA) has granted approval to taletrectinib (Ibtrozi, Nuvation Bio) for the treatment of adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), marking a significant advancement for patients with this rare and aggressive form of lung cancer. The approval, announced on June 11, 2025, is based on robust clinical trial data from the TRUST-I and TRUST-II studies, which demonstrated high and durable response rates in both treatment-naïve and previously treated patients.
Clinical Impact and Study Results
Taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI), is now available for use in both first- and later-line settings, regardless of prior TKI exposure. The drug was specifically designed to overcome some of the challenges seen with earlier TKIs, such as resistance and limited brain penetration. Clinical trial data suggest that taletrectinib offers greater brain penetration, a lower incidence of neurological side effects, and potentially improved efficacy over existing therapies.
The approval was supported by results from the TRUST-I and TRUST-II phase 2, single-arm, open-label studies, which included more than 300 patients globally—one of the largest clinical trial programs in this patient population. In the pooled analysis of 273 efficacy-evaluable patients, taletrectinib demonstrated an objective response rate (ORR) of 90% in TKI-naïve patients in TRUST-I and 85% in TRUST-II, with a majority of responses lasting at least 12 months. For patients previously treated with a ROS1 TKI, the ORR was 52% in TRUST-I and 62% in TRUST-II, with most responses lasting at least 6 months.
Importantly, taletrectinib also showed strong intracranial activity, with intracranial responses observed in 73% of TKI-naïve patients and 63% of TKI-pretreated patients with measurable brain metastases.
Safety and Tolerability
Taletrectinib was generally well tolerated, with most adverse events being low grade and manageable. The most common side effects included diarrhea, nausea, vomiting, dizziness, rash, constipation, and fatigue. Only 7% of patients discontinued treatment due to adverse events.
Expert Commentary
“Taletrectinib will likely become the preferred treatment option for advanced ROS1-positive NSCLC,” commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology. The drug’s ability to cross the blood-brain barrier and its favorable safety profile position it as a leading therapy for this patient population.
Availability
Taletrectinib, originally developed in China and approved there in January 2025, is expected to be available in the U.S. by mid-2025.
Disclaimer:
This news article is based on publicly available information and clinical trial results as of June 2025. It is intended for informational purposes only and should not be considered medical advice. Patients should consult their healthcare providers for guidance on diagnosis and treatment options. The author and publisher are not responsible for any actions taken based on the information provided.
